Japan in the Global Picture
* October 6, 2015
EFPIA Japan Days
Stefan Oschmann
Vice President, European Federation of Pharmaceutical Industries & Associations (EFPIA)
President, International Federation of Pharmaceutical Manufactures & Associations (IFPMA)
Vice Chairman of the Executive Board & Deputy CEO of Merck
www.efpia.eu
Europe & Japan Facing an Aging Society
Declining fertility rates & longer lifespans
creating new healthcare challenges
European Union (2014)
Source: The CIA Fact Book. (2014). European Reunion – Population Pyramid. Retrieved from
https://www.cia.gov/library/publications/the-world-factbook/geos/eu.html
Japan (2014)
Source: The CIA Fact Book. (2014). Japan – Population Pyramid. Retrieved form
https://www.cia.gov/library/publications/the-world-factbook/geos/ja.html
www.efpia.eu
2
Non-Communicable Diseases (NCDs):
a challenge for all health systems
900000
Number of Cancer Cases
800000
Cancer Incidence on the Rise in Japan
700000
600000
500000
400000
300000
200000
100000
0
Year
Source: Cancer Information Service, National Cancer Center. Matsuda A, Matsuda T, Shibata A, Katanoda K, Sobue T, Nishimoto H
and The Japan Cancer Surveillance Research Group. Cancer Incidence and Incidence Rates in Japan in 2008: A Study of 25
Population-based Cancer Registries for the Monitoring of Cancer Incidence in Japan (MCIJ) Project. Japanese Journal of Clinical
Oncology, 44(4): 388-396, 2013 Retrieved from http://ganjoho.jp/en/professional/statistics/table_download.html
www.efpia.eu
3
Universal Care: Lessons From Japan
Health Spending in OECD Countries as Percent of GDP
10.3% of GDP
Source: Organization for Economic Cooperation and Development (OECD). (2014). OECD Health Statistics 2014—How does
Japan compare? Retrieved from: http://www.oecd.org/els/health-systems/Briefing-Note-JAPAN-2014.pdf
www.efpia.eu
4
Taking a Proactive Approach to
Healthcare System Challenges
Improved PMDA Review Times
PMDA has nearly eliminated Japan’s ‘drug lag’
45
40
Average Review Time
35
30
10.1 Months!!
Number of NME
28.3
25
20
16.8
17.7
19.1
21.5
22.8
20
18.3
19
19.1
14.8
15
10
10.1
9.5
10.1
2011
2012
2013
5
0
2000
2001
2002
2003
2004
2005
2006
2007
2008
2009
Source: 医薬産業政策研究所. 2014. 日本における新薬の臨床開発と認審査の実積 (No. 63, p. 21).
2010
www.efpia.eu
5
The Environment for Innovation is Diverse
Origins of 252 new drugs discovered between
1998 and 2007
Biotechnology company; or universitydiscovered, transferred to biotechnology
company in the same region
Large pharmaceutical company
University-discovered, transferred to
biotechnology company in different
region
University-discovered, transferred to
pharmaceutical company
Small pharmaceutical company
Source: Kneller, Robert. (November 2010). The importance of new companies for drug discovery: origins of a decade of new
drugs. Nature Reviews Drug Discovery. Retrieved from http://www.nature.com/nrd/journal/v9/n11/full/nrd3251.html
www.efpia.eu
6
Creating an Environment for
Innovation & Health Improvement
Public-Private Partnerships (PPPs)
E.g., Academia-IndustryGovernment
Free Trade Agreements &
Increased FDI
EU-Japan
FTA
Reward for Innovation
E.g., Permanence of Pricing
Premium for Innovation
Innovative Regulatory Policy
E.g., Regulatory Harmonization,
Adaptive Licensing, Sakigake (FastTrack) Designation, etc.
Freeing Capital &
Transparency for Growth
E.g., Corporate Governance
Reform, Corporate Tax Rate
Reform
www.efpia.eu
7
Role of Public Private Partnerships (PPPs)
PPPs can both spur innovation and solve global health challenges
European Union
Japan
www.efpia.eu
8
The Necessary Components to
Improve Health
Innovation
Friendly
Policies
Disruptive
Innovation
Solutions
for
Healthcare
www.efpia.eu
9
Thank You!
EFPIA Brussels Office
Leopold Plaza Building * Rue du Trône 108
B-1050 Brussels * Belgium
Tel: + 32 (0)2 626 25 55
www.efpia.eu * [email protected]